Haemophilia and Protein C Deficiency
Bringing About Innovation in Haemophilia Treatment
The information contained in this page is intended for UK healthcare professionals only.
Baxter is committed to actively listening to and working with the haemophilia community to proactively shape the future of haemophilia by focusing on personalised innovations and solutions.
Baxter's range of haemophilia therapies allows clinicians to choose the appropriate therapy based on individual patient needs.
Specifically, Baxter is:
- Supporting advocacy through community participation, including through patient and clinician education and expanding patient access to therapy
- Advancing its portfolio through new therapies to address unmet clinical needs
- Supporting haemophilia through patient homecare
Our commitment to care continues through grants that support the creation of educational programs and symposia for medical healthcare professionals. These avenues offer opportunities for clinicians to engage in informative exchanges, and peer to peer discussion of latest evidence and clinical practice.